Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al‐Sawaf, Kirsten Fischer, Yi Meng Chang et al.|Nature Communications|2023Cited by 94
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1Vivien Kohlhaas, F. Thomas Wunderlich, Stuart J. Blakemore et al.|Blood|2020Cited by 88
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLChristoph Röllig, Leo Ruhnke, Christoph Schliemann et al.|Annals of Hematology|2025Cited by 4
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al‐Sawaf, Kirsten Fischer, Can Zhang et al.|Nature Communications|2023Cited by 3